Literature DB >> 1361125

Microtubule-independent choleresis and anti-cholestatic action of tauroursodeoxycholate in colchicine-treated rat liver.

T Nakai1, K Katagiri, M Hoshino, T Hayakawa, T Ohiwa.   

Abstract

In order to cast light on the anti-cholestatic and cytoprotective properties of ursodeoxycholic acid (UDCA), intrahepatic transport and secretion of bile salts and biliary phospholipids were investigated by using isolated perfused livers from colchicine-pretreated rats. Administration of taurocholic acid (TCA) after colchicine pretreatment induced marked cholestasis. Tauroursodeoxycholic acid (TUDCA) treatment, in contrast, was associated with maintenance of bile flow, with excretion rates of bile acids and phospholipids similar to those in control animals. Furthermore, TCA-induced cholestasis in colchicine-treated rat livers was clearly decreased by co-administration of TUDCA. Although simultaneous addition of UDCA also showed slight improvement, with or without taurine pre-treatment, biliary bile-salt analysis also showed that cholestasis was markedly remitted as the excretion of taurine-conjugated UDCA was increased. The results suggest that the cytoprotective and anti-cholestatic effects of TUDCA may be linked to action at the intrahepatocyte level, represented by mild detergent effects on organelle lipids and preservation of intracellular transport even under microtubule-dysfunctional conditions. In addition, it was indicated that cytoprotective effects of UDCA may also be exerted after its conjugation with taurine inside hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361125      PMCID: PMC1132054          DOI: 10.1042/bj2880613

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

1.  Evidence for a role of the microtubular system in the secretion of newly synthesized albumin and other proteins by the liver.

Authors:  Y Le Marchand; C Patzelt; F Assimacopoulos-Jeannet; E G Loten; B Jeanrenaud
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

2.  The binding of vincristine, vinblastine and colchicine to tubulin.

Authors:  R J Owellen; A H Owens; D W Donigian
Journal:  Biochem Biophys Res Commun       Date:  1972-05-26       Impact factor: 3.575

3.  [Therapeutic effect of ursodeoxycholic acid on sulpyrine-induced intrahepatic cholestasis. A case report].

Authors:  T Tomoda; H Moriwaki; H Onishi; E Tomita; T Takai; Y Muto; T Kumada; S Okuyama
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1984-11

4.  Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat.

Authors:  K Kitani; M Ohta; S Kanai
Journal:  Am J Physiol       Date:  1985-04

5.  Effects of colchicine and vinblastine on output of proteins into bile.

Authors:  P P Godfrey; L Lembra; R Coleman
Journal:  Biochem J       Date:  1982-10-15       Impact factor: 3.857

6.  Studies in the biosynthesis of hepatic and biliary lecithins.

Authors:  J A Balint; D A Beeler; D H Treble; H L Spitzer
Journal:  J Lipid Res       Date:  1967-09       Impact factor: 5.922

7.  Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

Authors:  R Poupon; Y Chrétien; R E Poupon; F Ballet; Y Calmus; F Darnis
Journal:  Lancet       Date:  1987-04-11       Impact factor: 79.321

8.  Intrahepatic sources of biliary-like micelles.

Authors:  A Reuben; R M Allen
Journal:  Biochim Biophys Acta       Date:  1986-03-21

9.  Tauroursodeoxycholate prevents taurocholate induced cholestasis.

Authors:  K Kitani; S Kanai
Journal:  Life Sci       Date:  1982-02-07       Impact factor: 5.037

10.  The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities.

Authors:  M J Armstrong; M C Carey
Journal:  J Lipid Res       Date:  1982-01       Impact factor: 5.922

View more
  5 in total

Review 1.  Application of Tauroursodeoxycholic Acid for Treatment of Neurological and Non-neurological Diseases: Is There a Potential for Treating Traumatic Brain Injury?

Authors:  Kyle R Gronbeck; Cecilia M P Rodrigues; Javad Mahmoudi; Eric M Bershad; Geoffrey Ling; Salam P Bachour; Afshin A Divani
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

2.  Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study.

Authors:  A Crosignani; P M Battezzati; K D Setchell; P Invernizzi; G Covini; M Zuin; M Podda
Journal:  Dig Dis Sci       Date:  1996-04       Impact factor: 3.199

3.  Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis.

Authors:  K D Setchell; C M Rodrigues; M Podda; A Crosignani
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

4.  Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice.

Authors:  Jae-Seong Yang; Jin Taek Kim; Jouhyun Jeon; Ho Sun Park; Gyeong Hoon Kang; Kyong Soo Park; Hong Kyu Lee; Sanguk Kim; Young Min Cho
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

5.  A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.

Authors:  Hong Ma; Minde Zeng; Ying Han; Huiping Yan; Hong Tang; Jifang Sheng; Heping Hu; Liufang Cheng; Qing Xie; Youfu Zhu; Guofeng Chen; Zhiliang Gao; Wen Xie; Jiyao Wang; Shanming Wu; Guiqiang Wang; Xiaohui Miao; Xiaoqing Fu; Liping Duan; Jie Xu; Lai Wei; Guangfeng Shi; Chengwei Chen; Minhu Chen; Qin Ning; Chen Yao; Jidong Jia
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.